scPharmaceuticals Dirección
Dirección controles de criterios 2/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
John Tucker
Chief Executive Officer (CEO)
US$1.8m
Compensación total
| Porcentaje del salario del CEO | 32.8% |
| Permanencia del CEO | 7.3yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 6.5yrs |
Actualizaciones recientes de la dirección
Recent updates
The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts
Mar 16
Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?
Nov 25scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients
Oct 20FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure
Oct 10Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?
Jan 11Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?
Sep 02scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX
Aug 26Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like
Mar 09How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?
Nov 24
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$604k | -US$55m |
| Sep 30 2023 | n/a | n/a | -US$50m |
| Jun 30 2023 | n/a | n/a | -US$45m |
| Mar 31 2023 | n/a | n/a | -US$40m |
| Dec 31 2022 | US$2m | US$580k | -US$37m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$31m |
| Mar 31 2022 | n/a | n/a | -US$29m |
| Dec 31 2021 | US$2m | US$550k | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$31m |
| Mar 31 2021 | n/a | n/a | -US$32m |
| Dec 31 2020 | US$2m | US$531k | -US$32m |
| Sep 30 2020 | n/a | n/a | -US$35m |
| Jun 30 2020 | n/a | n/a | -US$32m |
| Mar 31 2020 | n/a | n/a | -US$31m |
| Dec 31 2019 | US$1m | US$514k | -US$33m |
| Sep 30 2019 | n/a | n/a | -US$27m |
| Jun 30 2019 | n/a | n/a | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$29m |
| Dec 31 2018 | US$1m | US$494k | -US$29m |
| Sep 30 2018 | n/a | n/a | -US$31m |
| Jun 30 2018 | n/a | n/a | -US$31m |
| Mar 31 2018 | n/a | n/a | -US$28m |
| Dec 31 2017 | US$2m | US$380k | -US$24m |
Compensación vs. Mercado: La compensación total ($USD1.84M) de John está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD1.60M).
Compensación vs. Ingresos: La compensación de John ha aumentado mientras la empresa no es rentable.
CEO
John Tucker (60 yo)
7.3yrs
Permanencia
US$1,838,662
Compensación
Mr. John H. Tucker has been the Chief Executive Officer and President of scPharmaceuticals Inc. (alternate name: scPharmaceuticals LLC) since January 30, 2017 and serves as its Principal Executive Officer...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 8.3yrs | US$1.84m | 0.25% $ 444.2k | |
| Independent Director | 9.4yrs | US$184.55k | 0.16% $ 281.5k | |
| Independent Chairman of the Board | 7.9yrs | US$227.05k | 0.014% $ 24.5k | |
| Independent Director | 10.2yrs | US$189.55k | 0% $ 0 | |
| Independent Director | 6.5yrs | US$187.05k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 3.3yrs | US$182.05k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$187.05k | 0% $ 0 | |
| Independent Director | 5.9yrs | US$197.05k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$187.05k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
6.5yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de SCPH se considera experimentada (6.4 años de antigüedad promedio).